In 1978, Biocon limited was laid out and the association has from that point forward well versed in the examination and treatment of different fatal sicknesses that influence people. These incorporate disease, diabetes among others. Because they are a multinational corporation, their goods are sold in numerous nations all over the world. The Biocon Organization is effectively fabricating biotechnological items and gives research administrations.
Biocon Share Price Target 2024-2030
Prediction of Biocon’s share price is done every five years and lasts for five years, with predictions made for five years. The following offer value expectation would be acted in 2025 that will be named as Biocon Offer Value Forecast 2025 in which the costs of offers will be anticipated the cycle will continue to proceed.
Biocon Share Price Target Today Update
Putting resources into stocks requires informed decisions basically founded on intensive examination and expert appraisal. You have come to the right place if you are interested in Biocon stocks. The Biocon percentage fee goal from 2024 to 2030 will be covered in depth in this blog. Our evaluation is basically founded on the organization’s development, execution, and fate prospects, guaranteeing you have the data you want to make a legitimate financing inclination.
What Is Biocon Limited?
Biocon Limited undertaking practices inside the turn of events and creation of conventional dynamic drug components (APIs) and is engaged with the investigations of novel biologics. Biocon is committed to giving up less expensive medical care arrangements around the world.
Read More:-
Dhanlaxmi Bank Share Price Target
Biocon Business Profile
The Biocon Ltd. (Biocon) is a pharmaceutical manufacturing biotechnology company. It spends significant time in innovative work of therapies for ongoing sicknesses like disease, diabetes and auto resistant illnesses. In addition, the business produces complex biologics, biosimilars, active pharmaceutical ingredients (APIs), branded formulations, monoclonal antibodies (MAbs), rh-Insulin, and insulin analogs.
- Biosimilars: A few extra administrations by the organization incorporate agreement producing, drug permitting, examination, and improvement of little and enormous particles for biotechnology as well as drug firms all over the planet. The organization has a functional presence in UK, Ireland, US, Switzerland, UAE and Malaysia.
- Research Services: Syngene, Biocon’s research services division, is listed on its own. It gives bound together revelation examination, advancement, and assembling administrations across different businesses including drugs, biotechnology, nourishment, creature wellbeing, purchaser products, and specialty synthetic substances.
- Generics: It is the principal Indian company among U.S.D FDA endorsed organizations which produce Lovastatin that is a maturation based statin Programming interface utilized for cholesterol decrease. The Programming interface portfolio includes in excess of 50 items across various restorative regions like cardiovascular sicknesses, enemies of diabetics, immunosuppressants, oncology high powerful Programming interface (HPAPI) and some specialty drug particles.
- Novel Biologics: In India, under the brand name ALZUMAb, the organization sent off Nimotuzumab, the main natively created monoclonal neutralizer for head and neck malignant growth, and Itolizumab, the primary novel enemy of CD6 monoclonal immune response on the planet for psoriasis. Bicara Therapeutics (a Boston, USA-based partner) is engaged with creating bifunctional antibodies that exploit late headway made in immuno-oncology.
- Manufacturing Expansion: During the monetary year 2024, Biocon purchased an Oral Strong Dose creation unit from New Jersey USA. By the end of FY2025, the immunosuppressant unit in Vizag will be qualified to supply commercial products in India.
Biocon Fundamentals & Quarterly Results
| Metric | Value |
| Market Cap | ₹ 42,213 Cr. |
| Current Price | ₹ 352 |
| High / Low | ₹ 377 / 218 |
| Stock P/E | 27.0 |
| Book Value | ₹ 165 |
| Dividend Yield | 0.14 % |
| ROCE | 5.96 % |
| ROE | 5.25 % |
| Face Value | ₹ 5.00 |
| FCF Prev Ann | ₹ 129 Cr. |
| Debt to Equity | 0.82 |
| Debt Preceding Year | ₹ 18,019 Cr. |
| Reserves | ₹ 19,183 Cr. |
| Quick Ratio | 0.65 |
| Current Ratio | 0.97 |
| Free Cash Flow | ₹ 1,046 Cr. |
Biocon Quarterly Results
| Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | |
| Sales (₹ Cr.) | 2,140 | 2,320 | 2,941 | 3,774 | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 |
| Expenses (₹ Cr.) | 1,783 | 1,877 | 2,352 | 2,817 | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 |
| Operating Profit (₹ Cr.) | 356 | 442 | 589 | 957 | 681 | 717 | 903 | 913 | 620 |
| OPM % | 17% | 19% | 20% | 25% | 20% | 21% | 23% | 23% | 18% |
| Other Income (₹ Cr.) | 78 | 48 | -193 | 152 | 94 | 134 | 587 | 40 | 1,166 |
| Interest (₹ Cr.) | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 |
| Depreciation (₹ Cr.) | 218 | 231 | 301 | 364 | 358 | 389 | 414 | 407 | 405 |
| Profit before tax (₹ Cr.) | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 |
| Tax % | 15% | 64% | -19% | 17% | 19% | 19% | 7% | 30% | 25% |
| Net Profit (₹ Cr.) | 167 | 82 | -21 | 414 | 149 | 173 | 753 | 223 | 862 |
| EPS (₹) | 1.20 | 0.39 | -0.35 | 2.61 | 0.84 | 1.05 | 5.50 | 1.13 | 5.49 |
CAGR Report
| Metric | 10 Years | 5 Years | 3 Years | TTM / 1 Year |
| Compounded Sales Growth | 18% | 22% | 27% | 19% |
| Compounded Profit Growth | 9% | 6% | 11% | 137% |
| Stock Price CAGR | 16% | 9% | 1% | 38% |
| Return on Equity | 8% | 7% | 6% | 5% |
Read More:-
L&T Finance Share Price Target
Biocon Share holding Pattern
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Jun 2024 | |
| Promoters | 60.67% | 60.67% | 60.67% | 60.67% | 60.64% | 60.64% | 60.64% | 60.64% |
| FIIs | 16.99% | 17.90% | 14.98% | 16.30% | 15.62% | 10.20% | 5.63% | 5.90% |
| DIIs | 3.93% | 4.38% | 7.32% | 7.14% | 8.36% | 11.89% | 13.69% | 14.29% |
| Public | 16.91% | 15.62% | 15.80% | 14.96% | 14.76% | 16.70% | 19.74% | 18.90% |
| Others | 1.50% | 1.43% | 1.23% | 0.93% | 0.63% | 0.55% | 0.32% | 0.28% |
| No. of Shareholders | 1,34,488 | 1,53,793 | 2,06,996 | 3,11,349 | 3,47,911 | 4,11,086 | 4,70,261 | 4,43,513 |
Biocon Share Price Target 2024-2030 Forecast
| Year | Initial Target | Mid-Year Target | Year-End Target |
| 2024 | ₹419.2 | ₹496.13 | ₹542.29 |
| 2025 | ₹553 | ₹519 | ₹620 |
| 2026 | ₹632 | ₹595 | ₹711 |
| 2027 | ₹725 | ₹682 | ₹813 |
| 2028 | ₹829 | ₹779 | ₹930 |
| 2029 | ₹949 | ₹891 | ₹1064 |
| 2030 | ₹1085 | ₹1020 | ₹1217 |
BIOCON Share Price Target 2025
| Month | Target |
| January | ₹553 |
| February | ₹564 |
| March | ₹575 |
| April | ₹556 |
| May | ₹537 |
| June | ₹519 |
| July | ₹540 |
| August | ₹562 |
| September | ₹584 |
| October | ₹596 |
| November | ₹608 |
| December | ₹620 |
BIOCON Share Price Target 2026
| Month | Target |
| January | ₹632 |
| February | ₹645 |
| March | ₹658 |
| April | ₹636 |
| May | ₹615 |
| June | ₹595 |
| July | ₹619 |
| August | ₹644 |
| September | ₹670 |
| October | ₹683 |
| November | ₹697 |
| December | ₹711 |
BIOCON Share Price Target 2027
| Month | Target |
| January | ₹725 |
| February | ₹740 |
| March | ₹755 |
| April | ₹730 |
| May | ₹706 |
| June | ₹682 |
| July | ₹709 |
| August | ₹737 |
| September | ₹766 |
| October | ₹781 |
| November | ₹797 |
| December | ₹813 |
BIOCON Share Price Target 2028
| Month | Target |
| January | ₹829 |
| February | ₹846 |
| March | ₹863 |
| April | ₹834 |
| May | ₹806 |
| June | ₹779 |
| July | ₹810 |
| August | ₹842 |
| September | ₹876 |
| October | ₹894 |
| November | ₹912 |
| December | ₹930 |
Read More:-
Cochin Shipyard Share Price Target
BIOCON Share Price Target 2029
| Month | Target |
| January | ₹949 |
| February | ₹968 |
| March | ₹987 |
| April | ₹954 |
| May | ₹922 |
| June | ₹891 |
| July | ₹927 |
| August | ₹964 |
| September | ₹1003 |
| October | ₹1023 |
| November | ₹1043 |
| December | ₹1064 |
BIOCON Share Price Target 2030
| Month | Target |
| January | ₹1085 |
| February | ₹1107 |
| March | ₹1129 |
| April | ₹1091 |
| May | ₹1055 |
| June | ₹1020 |
| July | ₹1061 |
| August | ₹1103 |
| September | ₹1147 |
| October | ₹1170 |
| November | ₹1193 |
| December | ₹1217 |
Points Before Investing in Biocon limited:-
- All the data with respect to the Biocon limited should be seen through and risk factors should be thought of.
- The company must determine the amount and number of shares to purchase, and no one else should be able to influence this number.
- The Biocon Limited is a mid-cap company, which increases the stock exchange’s various risk factors.
- The classification, speculation returns, reserve type should be checked of the specific asset you are wanting to put resources into the organization.
- The expense ramifications of the organization should be dealt with also.
Final Words
The Biocon limited is connected with the clinical necessities, this organization investigates about the different serious human illnesses like disease, diabetes. It is positioned eighth number too in the pharma area, which plainly connotes the great presentation in the drug field. It is a global organization too. In addition, the business does well on stock exchanges, and the share price has increased by 1.7% since the previous closing price. This company is regarded as a good investment on the Indian stock exchanges because its prices continue to rise and there are significant opportunities for profit.
Stay Updated with the Latest News and Trends
Discover the latest in tech, exams, Sarkari results, and more with our platform. We bring you fresh updates and expert insights to keep you informed and ahead. Join us today and stay on top of the most important developments!